Revive Therapeutics Submits Updated Briefing Package in Support of Upcoming Type C Meeting Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
Stock Information for Revive Therapeutics Ltd
Loading
Please wait while we load your information from QuoteMedia.